Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy

Stroke. 2010 Jun;41(6):1163-8. doi: 10.1161/STROKEAHA.110.580811. Epub 2010 Apr 22.

Abstract

Background and purpose: The object of our study was to compare the effect of high-dose vs low-dose atorvastatin vs nonstatin-based treatment (cholestyramine plus sitosterol) on cell composition of carotid plaque.

Methods: We recruited 60 hypercholesterolemic patients (total cholesterol, 5.83-7.64 mmol/L) eligible for carotid endarterectomy. Three months before surgery, patients were randomized into 3 groups (n=20) receiving atorvastatin 10 mg/day (AT-10) or atorvastatin 80 mg/day (AT-80) or cholestyramine 8 g/day plus sitosterol 2.5 g/day. Analysis of cell composition was performed on endarterectomy specimens.

Results: The 3 treatments resulted in a significant reduction of total cholesterol and low-density lipoprotein cholesterol (LDL-C), although the decrease in total cholesterol and LDL-C was of smaller magnitude in the cholestyramine plus sitosterol group. The 3 regimens did not influence the levels of inflammatory markers (including high-sensitivity C-reactive protein). Macrophage content was significantly lower in the AT-10 group plaques compared to the cholestyramine plus sitosterol group. It was further reduced in the AT-80 group plaques. These differences were no longer significant after adjustment for changes in LDL-C. No difference in lymphocyte number was observed among treatments, whereas the content of smooth muscle cells was higher in the AT- 80 group. An inverse association was observed between LDL-C changes in the 3 groups and macrophage content in the plaques.

Conclusions: Short-term treatment with high-dose statin is superior to a nonstatin lipid-lowering regimen in reducing the macrophage cell content within atherosclerotic lesions, but this effect was determined by the degree of LDL-C-lowering.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticholesteremic Agents / administration & dosage*
  • Atherosclerosis* / blood
  • Atherosclerosis* / pathology
  • Atherosclerosis* / therapy
  • Atorvastatin
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Cholesterol, LDL / blood
  • Cholestyramine Resin / administration & dosage*
  • Endarterectomy, Carotid*
  • Female
  • Heptanoic Acids / administration & dosage*
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / pathology
  • Hypercholesterolemia / therapy
  • Lymphocyte Count
  • Macrophages / pathology*
  • Male
  • Pyrroles / administration & dosage*
  • Sitosterols / administration & dosage*

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL
  • Heptanoic Acids
  • Pyrroles
  • Sitosterols
  • Cholestyramine Resin
  • gamma-sitosterol
  • C-Reactive Protein
  • Atorvastatin